Source: https://www.tripdatabase.com/search?criteria=Plaque&page=3
Timestamp: 2020-02-20 01:46:11
Document Index: 123770629

Matched Legal Cases: ['§ 35', '§35', '§ 35', '§35', '§ 35', '§ 35', '§35', '§ 35', '§35', '§ 35', '§35']

41. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value
Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2018 Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value Condition Update Final Evidence Report August 03, 2018 Prepared for: ©Institute for Clinical and Economic Review, 2018 Page i Final Evidence Report: Plaque Psoriasis Condition Update ICER Staff/Consultants University of Washington (...) ii Final Evidence Report: Plaque Psoriasis Condition Update About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. The funding for this report comes from government grants and non-profit foundations, with the largest single funder being the Laura and John Arnold
42. Brodalumab (Kyntheum) - plaque psoriasis
Brodalumab (Kyntheum) - plaque psoriasis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 18 May 2017 EMA/381484/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Kyntheum International non-proprietary (...) to the European Medicines Agency (EMA) for Kyntheum, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. On 10 October 2016, the applicant changed from AstraZeneca UK Limited to LEO Pharma A/S. The applicant applied for the following indication: Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC
43. Tremfya - guselkumab - Psoriasis, moderate to severe plaque
Tremfya - guselkumab - Psoriasis, moderate to severe plaque guselkumab | CADTH.ca Find the information you need guselkumab guselkumab Last Updated: April 5, 2018 Result type: Reports Project Number: SR0530-000 Product Line: Generic Name: guselkumab Brand Name: Tremfya Manufacturer: Janssen Inc. Indications: Psoriasis, moderate to severe plaque Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: February 21, 2018 Recommendation Type: Reimburse with clinical
44. Etanercept (Lifmior) - rheumatoid arthritis, certain forms of juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis
45. Siliq - brodalumab - Psoriasis, moderate to severe plaque
Siliq - brodalumab - Psoriasis, moderate to severe plaque brodalumab | CADTH.ca Find the information you need brodalumab brodalumab Last Updated: July 16, 2018 Result type: Reports Project Number: SR0547-000 Product Line: Generic Name: brodalumab Brand Name: Siliq Manufacturer: Valeant Canada LP Indications: Psoriasis, moderate to severe plaque Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: June 20, 2018 Recommendation Type: Reimburse with clinical
46. Brodalumab (Siliq) - To treat adults with moderate-to-severe plaque psoriasis
Brodalumab (Siliq) - To treat adults with moderate-to-severe plaque psoriasis Siliq (brodalumab) U.S. Department of Health and Human Services Search FDA Submit search Siliq (brodalumab) Siliq Company: Valeant Pharmaceuticals Application No.: 761032 Approval Date: 02/15/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created
47. Dimethyl fumarate (Skilarence) for the treatment of plaque psoriasis in adults
Dimethyl fumarate (Skilarence) for the treatment of plaque psoriasis in adults Dimethyl fumarate (Skilarence®) for the treatment of plaque psoriasis in adults | Report | National Health Care Institute You are here: Dimethyl fumarate (Skilarence®) for the treatment of plaque psoriasis in adults Search within English part of National Health Care Institute Search Dimethyl fumarate (Skilarence®) for the treatment of plaque psoriasis in adults The Minister of Health, Welfare and Sport (WVS) asked
48. Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease
Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease '); } else { document.write(' '); } ACE | Infliximab for the treatment of rheumatoid arthritis ankylosing spondylitis psoriatic arthritis plaque psoriasis ulcerative colitis and crohns disease Search > > Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis (...) and Crohn's disease - Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease Published on 1 March 2018 Guidance Recommendation The Ministry of Health’s Drug Advisory Committee has recommended: Infliximab biosimilar (Remsima) 100mg vial for the treatment of: Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, ulcerative
49. In Systemically Healthy Patients with Gingivitis, Mechanical Plaque Control with The Adjunctive Use of Essential Oils Containing Mouthrinses (MMEO) Reduced Plaque and Gingivitis Greater Than Mechanical Methods (MM) Alone
In Systemically Healthy Patients with Gingivitis, Mechanical Plaque Control with The Adjunctive Use of Essential Oils Containing Mouthrinses (MMEO) Reduced Plaque and Gingivitis Greater Than Mechanical Methods (MM) Alone UTCAT2944, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title In Systemically Healthy Patients with Gingivitis, Mechanical Plaque Control with The Adjunctive Use of Essential Oils Containing Mouthrinses (...) (MMEO) Reduced Plaque and Gingivitis Greater Than Mechanical Methods (MM) Alone Clinical Question In healthy patients with gingivitis, does the adjunctive use of essential oils containing mouthrinses with mechanical methods reduce plaque and gingivitis more than mechanical methods alone? Clinical Bottom Line The use of essential oils mouthrinse as an adjunctive to mechanical plaque removal provided statistically significantly greater odds of having healthy gingiva and in reducing plaque
50. Cartilage Oligomeric Matrix Protein Associates With a Vulnerable Plaque Phenotype in Human Atherosclerotic Plaques. (Abstract)
Cartilage Oligomeric Matrix Protein Associates With a Vulnerable Plaque Phenotype in Human Atherosclerotic Plaques. Background and Purpose- Extracellular matrix proteins are important in atherosclerotic disease by influencing plaque stability and cellular behavior but also by regulating inflammation. COMP (cartilage oligomeric matrix protein) is present in healthy human arteries and expressed by smooth muscle cells. A recent study showed that transplantation of COMP-deficient bone marrow (...) to apoE-/- mice increased atherosclerotic plaque formation, indicating a role for COMP also in bone marrow-derived cells. Despite the evidence of a role for COMP in murine atherosclerosis, knowledge is lacking about the role of COMP in human atherosclerotic disease. Methods- In the present study, we investigated if COMP was associated with a stable or a vulnerable human atherosclerotic plaque phenotype by analyzing 211 carotid plaques for COMP expression using immunohistochemistry. Results- Plaque
51. Heterogeneity of Plaque Structural Stress Is Increased in Plaques Leading to MACE: Insights From the PROSPECT Study. Full Text available with Trip Pro
Heterogeneity of Plaque Structural Stress Is Increased in Plaques Leading to MACE: Insights From the PROSPECT Study. This study sought to determine if plaque structural stress (PSS) and other plaque stress parameters are increased in plaques that cause future major adverse cardiovascular events (MACE) and if incorporating these parameters improves predictive capability of intravascular ultrasonography (IVUS).Less than 10% of coronary plaques identified as high-risk by intravascular imaging (...) result in subsequent MACE. Thus, more specific measurements of plaque vulnerability are required for effective risk stratification.Propensity score matching in the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study plaque cohort resulted in 35 nonculprit lesions (NCL) associated with future MACE and 66 matched NCL that remained clinically silent. PSS was calculated by finite element analysis as the mechanical loading within the plaque structure
52. Impact of combined plaque structural stress and wall shear stress on coronary plaque progression, regression, and changes in composition. Full Text available with Trip Pro
Impact of combined plaque structural stress and wall shear stress on coronary plaque progression, regression, and changes in composition. The focal distribution of atherosclerotic plaques suggests that local biomechanical factors may influence plaque development.We studied 40 patients at baseline and over 12 months by virtual-histology intravascular ultrasound and bi-plane coronary angiography. We calculated plaque structural stress (PSS), defined as the mean of the maximum principal stress (...) at the peri-luminal region, and wall shear stress (WSS), defined as the parallel frictional force exerted by blood flow on the endothelial surface, in areas undergoing progression or regression. Changes in plaque area, plaque burden (PB), necrotic core (NC), fibrous tissue (FT), fibrofatty tissue, and dense calcium were calculated for each co-registered frame. A total of 4029 co-registered frames were generated. In areas with progression, high PSS was associated with larger increases in NC and small
53. [Secukinumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V (new scientific findings)]
[Secukinumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V (new scientific findings)] Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche erkenntnisse); dossierbewertung [Secukinumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V (new scientific findings)] Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche erkenntnisse); dossierbewertung [Secukinumab (plaque (...) psoriasis) - benefit assessment according to §35a Social Code Book V (new scientific findings)] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue
54. [Ixekizumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V]
[Ixekizumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V] Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07 [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07 [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und (...) Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07. [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Cologne
55. [Secukinumab (plaque psoriasis) - addendum to Commission A17-08]
[Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31 [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31 [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31. [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 529. 2017 Final publication URL Indexing Status Subject indexing
56. [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07]
[Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30 [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30 [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ixekizumab (Plaque Psoriasis): Addendum zum Auftrag A17-07; Auftrag A17-30. [Ixekizumab (plaque psoriasis) - addendum to Commission A17-07] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 528. 2017 Final publication URL Indexing Status Subject indexing assigned
57. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value
Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2016 Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value Final Evidence Report December 2, 2016 Prepared for ©Institute for Clinical and Economic Review, 2016 Page ii Final Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table (...) Institute for Clinical and Economic Review, 2016 Page iii Final Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table of Contents Disclosure Statement: Dr. Linder owns stock in Amgen, Biogen, and Eli Lily, has contingent value rights in Sanofi Genzyme (related to alemtuzumab for multiple sclerosis); in the past 3 years, Dr. Linder has received grant support from Astellas Pharma on an unrelated topic (overactive bladder) and Clintrex, which
58. Dental water jets have not been demonstrated to be more effective than floss at removing interproximal plaque.
Dental water jets have not been demonstrated to be more effective than floss at removing interproximal plaque. UTCAT3279, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Dental water jets have not been demonstrated to be more effective than floss at removing interproximal plaque. Clinical Question Are dental water jets more effective than floss in the removal of interproximal plaque? Clinical Bottom Line (...) There is insufficient evidence at this time to indicate that either the dental water jet or dental floss are more effective at removing interproximal plaque. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Salzer/2015 6 systematic reviews/3534 patients Meta-Analysis Key results Of the two systematic reviews regarding the use of dental floss, one found no statistically significant benefit of flossing in addition
59. Turmeric in a Mouth Rinse or in Gel Form Can Be Used to Reduce Plaque Accumulation and to Prevent and Treat Gingivitis as Effectively as a Chlorhexidine Mouth Rinse
60. Chlorhexidine Mouth Rinse Twice a Day Is at Least as Effective as Dental Floss in Reducing Plaque Buildup